117 related articles for article (PubMed ID: 31135601)
1. Diagnostic and prognostic value of glucose transporters in melanocytic lesions.
Ruby KN; Liu CL; Li Z; Felty CC; Wells WA; Yan S
Melanoma Res; 2019 Dec; 29(6):603-611. PubMed ID: 31135601
[TBL] [Abstract][Full Text] [Related]
2. Monosomy-3 Alters the Expression Profile of the Glucose Transporters GLUT1-3 in Uveal Melanoma.
Maaßen T; Vardanyan S; Brosig A; Merz H; Ranjbar M; Kakkassery V; Grisanti S; Tura A
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33302435
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and Prognostic Value of ProEx C and GLUT1 in Melanocytic Lesions.
Yan S; Coffing BN; Li Z; Xie H; Brennick JB; Beg HA; Froehlich HM; Wells WA
Anticancer Res; 2016 Jun; 36(6):2871-80. PubMed ID: 27272799
[TBL] [Abstract][Full Text] [Related]
4. The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.
Pinheiro C; Miranda-Gonçalves V; Longatto-Filho A; Vicente AL; Berardinelli GN; Scapulatempo-Neto C; Costa RF; Viana CR; Reis RM; Baltazar F; Vazquez VL
Cell Cycle; 2016 Jun; 15(11):1462-70. PubMed ID: 27105345
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions.
Parente P; Coli A; Massi G; Mangoni A; Fabrizi MM; Bigotti G
J Exp Clin Cancer Res; 2008 Sep; 27(1):34. PubMed ID: 18764953
[TBL] [Abstract][Full Text] [Related]
6. Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.
Dundr P; Simon K; Němejcová K; Bártů M; Tichá I; Michálková R; Jakša R; Věcková Z; Kodet O
Melanoma Res; 2019 Apr; 29(2):157-162. PubMed ID: 30422880
[TBL] [Abstract][Full Text] [Related]
7. Expression of Glut-1 in Malignant Melanoma and Melanocytic Nevi: an Immunohistochemical Study of 400 Cases.
Důra M; Němejcová K; Jakša R; Bártů M; Kodet O; Tichá I; Michálková R; Dundr P
Pathol Oncol Res; 2019 Jan; 25(1):361-368. PubMed ID: 29128957
[TBL] [Abstract][Full Text] [Related]
8. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
9. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
[TBL] [Abstract][Full Text] [Related]
10. Differential regulation of glucose transporters mediated by CRH receptor type 1 and type 2 in human placental trophoblasts.
Gao L; Lv C; Xu C; Li Y; Cui X; Gu H; Ni X
Endocrinology; 2012 Mar; 153(3):1464-71. PubMed ID: 22234467
[TBL] [Abstract][Full Text] [Related]
11. Expression of facilitative glucose transporter isoforms in human brain tumors.
Nagamatsu S; Sawa H; Wakizaka A; Hoshino T
J Neurochem; 1993 Dec; 61(6):2048-53. PubMed ID: 8245960
[TBL] [Abstract][Full Text] [Related]
12. PRAME Expression in Melanocytic Tumors.
Lezcano C; Jungbluth AA; Nehal KS; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Nov; 42(11):1456-1465. PubMed ID: 30045064
[TBL] [Abstract][Full Text] [Related]
13. Melanomas Associated With Blue Nevi or Mimicking Cellular Blue Nevi: Clinical, Pathologic, and Molecular Study of 11 Cases Displaying a High Frequency of GNA11 Mutations, BAP1 Expression Loss, and a Predilection for the Scalp.
Costa S; Byrne M; Pissaloux D; Haddad V; Paindavoine S; Thomas L; Aubin F; Lesimple T; Grange F; Bonniaud B; Mortier L; Mateus C; Dreno B; Balme B; Vergier B; de la Fouchardiere A
Am J Surg Pathol; 2016 Mar; 40(3):368-77. PubMed ID: 26645730
[TBL] [Abstract][Full Text] [Related]
14. IMP-3 EXPRESSION IN BENIGN MELANOCYTIC NEVI, DYSPLASTIC NEVI AND MALIGNANT MELANOMA: PRELIMINARY FINDINGS IN BULGARIAN PATIENTS.
Chokoeva AA; Ananiev J; Wollina U; Tana C; Lotti T; Cardoso JC; Tchernev G
J Biol Regul Homeost Agents; 2015; 29(3):695-9. PubMed ID: 26403409
[TBL] [Abstract][Full Text] [Related]
15. Staining of melanocytic neoplasms by melanoma antigen recognized by T cells.
Mehregan DR; Hamzavi I
Am J Dermatopathol; 2000 Jun; 22(3):247-50. PubMed ID: 10871068
[TBL] [Abstract][Full Text] [Related]
16. Gene expression of GLUT3 and GLUT1 glucose transporters in human brain tumors.
Boado RJ; Black KL; Pardridge WM
Brain Res Mol Brain Res; 1994 Nov; 27(1):51-7. PubMed ID: 7877454
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases.
Dai DL; Martinka M; Li G
J Clin Oncol; 2005 Mar; 23(7):1473-82. PubMed ID: 15735123
[TBL] [Abstract][Full Text] [Related]
18. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
19. Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma.
Nguyen J; Bernert R; In K; Kang P; Sebastiao N; Hu C; Hastings KT
Melanoma Res; 2016 Apr; 26(2):125-37. PubMed ID: 26930048
[TBL] [Abstract][Full Text] [Related]
20. PRAME expression in melanocytic lesions of the nail.
Parra O; Linos K; Li Z; Yan S
J Cutan Pathol; 2022 Jul; 49(7):610-617. PubMed ID: 35294053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
